P
Paola Fazi
Researcher at Sapienza University of Rome
Publications - 163
Citations - 9136
Paola Fazi is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Internal medicine & Myeloid leukemia. The author has an hindex of 38, co-authored 145 publications receiving 7950 citations. Previous affiliations of Paola Fazi include University of Bari & University of Bologna.
Papers
More filters
Journal ArticleDOI
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Brunangelo Falini,Christina Mecucci,Enrico Tiacci,Myriam Alcalay,Roberto Rosati,Laura Pasqualucci,Roberta La Starza,Daniela Diverio,Emanuela Colombo,Antonella Santucci,Barbara Bigerna,Roberta Pacini,Alessandra Pucciarini,Arcangelo Liso,Marco Vignetti,Paola Fazi,Natalia Meani,Valentina Pettirossi,Giuseppe Saglio,Franco Mandelli,Francesco Lo-Coco,Pier Giuseppe Pelicci,Massimo F. Martelli +22 more
TL;DR: Cytoplasmic NPM is a characteristic feature of a large subgroup of patients with AML who have a normal karyotype, NPM gene mutations, and responsiveness to induction chemotherapy.
Journal ArticleDOI
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Francesco Lo-Coco,Giuseppe Avvisati,Marco Vignetti,Christian Thiede,Simona Iacobelli,Felicetto Ferrara,Paola Fazi,Laura Cicconi,E. Di Bona,Giorgina Specchia,Simona Sica,Mariadomenica Divona,Alessandro Levis,Walter Fiedler,Elisa Cerqui,Massimo Breccia,Giuseppe Fioritoni,Mario Cazzola,L. Melillo,Enrica Morra,Bernd Hertenstein,Mohammed Wattad,Michael Lübbert,Mathias Hänel,Norbert Schmitz,Alessandro Rambaldi,G. La Nasa,Mario Luppi,Fabio Ciceri,Olimpia Finizio,Adriano Venditti,Francesco Fabbiano,Konstanze Döhner,M. Sauer,Arnold Ganser,Sergio Amadori,Franco Mandelli,Hartmut Döhner,Gerhard Ehninger +38 more
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Journal ArticleDOI
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
Robin Foà,Antonella Vitale,Marco Vignetti,Giovanna Meloni,Anna Guarini,Maria Stefania De Propris,Loredana Elia,Francesca Paoloni,Paola Fazi,Giuseppe Cimino,Francesco Nobile,Felicetto Ferrara,Carlo Castagnola,Simona Sica,Pietro Leoni,Eliana Zuffa,Claudio Fozza,Mario Luppi,Anna Candoni,Ilaria Iacobucci,Simona Soverini,Franco Mandelli,Giovanni Martinelli,Michele Baccarani +23 more
TL;DR: In adult Ph(+) ALL, induction treatment with dasatinib plus steroids is associated with a CHR in virtually all patients, irrespective of age, good compliance, no deaths, and a very rapid debulking of the neoplastic clone.
Journal ArticleDOI
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial
Stefan Suciu,Franco Mandelli,Theo de Witte,Robert Zittoun,Eugenio Gallo,Boris Labar,Gennaro De Rosa,A Belhabri,Rosario Giustolisi,Richard Delarue,Vincenzo Liso,Salvatore Mirto,Giuseppe Leone,Jean-Henri Bourhis,Giuseppe Fioritoni,Ulrich Jehn,Sergio Amadori,Paola Fazi,Anne Hagemeijer,Roel Willemze +19 more
TL;DR: Intention-to-treat analysis revealed that the 4-year disease-free survival (DFS) rate of patients with a donor versus those without a donor was 52.2% versus 42.2%, and the strategy to perform early allo-SCT led to better overall results than auto-S CT, especially for younger patients or those with bad/very bad risk cytogenetics.
Journal ArticleDOI
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol
Marco Vignetti,Paola Fazi,Giuseppe Cimino,Giovanni Martinelli,Francesco Di Raimondo,Felicetto Ferrara,Giovanna Meloni,Achille Ambrosetti,Giovanni Quarta,Livio Pagano,Giovanna Rege-Cambrin,Loredana Elia,Raffaello Bertieri,Luciana Annino,Robin Foà,Michele Baccarani,Franco Mandelli +16 more
TL;DR: This study shows that elderly Ph(+) patients with ALL-often considered eligible only for palliative treatment strategies-may benefit from an imatinib-steroids protocol, which does not require chemotherapy nor a long hospitalization, is feasible, highly active, and associated with a good quality of life.